Showing results (11-20 of 36) with videos related to
Sort By:
Pageof 4
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 19, 2010
IFN-gamma treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent mannerIdo D Weiss, Ori Wald, Hanna Wald, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2006
Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune responseArnon Karni, Michal Abraham, Alon Monsonego, et al.Cytokine|March 8, 2011
Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under physiological conditionsIdo D Weiss, Hadas Shoham, Ori Wald, et al.Frontiers in Immunology|December 9, 2017
Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and InflammationMichal Abraham, Hanna Wald, Dalit Vaizel-Ohayon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2013
Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140Katia Beider, Elena Ribakovsky, Michal Abraham, et al.Journal of Hematology & Oncology|October 10, 2022
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progressionKatia Beider, Valeria Voevoda-Dimenshtein, Ali Zoabi, et al.Oncotarget|December 20, 2014
Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotypeKatia Beider, Hanna Bitner, Merav Leiba, et al.Frontiers in Immunology|April 23, 2025
Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1Shira Hagbi-Levi, Michal Abraham, Lika Gamaev, et al.Molecular Cancer Therapeutics|February 8, 2014
Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivoKatia Beider, Merav Darash-Yahana, Orly Blaier, et al.Plos One|April 3, 2009
Interaction between CXCR4 and CCL20 pathways regulates tumor growthKatia Beider, Michal Abraham, Michal Begin, et al.Pageof 4